Equity Overview
Price & Market Data
Price: $6.10
Daily Change: +$0.228 / 3.75%
Daily Range: $6.02 - $6.19
Market Cap: $1,012,171,712
Daily Volume: 4,361
Performance Metrics
1 Week: 4.82%
1 Month: 1.03%
3 Months: -17.21%
6 Months: -28.41%
1 Year: 33.11%
YTD: -25.22%
Company Details
Employees: 435
Sector: Health technology
Industry: Biotechnology
Country: United States
Details
Xeris Biopharma Holdings, Inc., a commercial-stage biopharmaceutical company, engages in developing and commercializing therapies for chronic endocrine and neurological diseases in Illinois. It offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia in pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It is also developing XP-8121, a once-weekly subcutaneous injection of levothyroxine that is in phase 3 clinical trial for the treatment of hypothyroidism. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.